Showing 5491-5500 of 6964 results for "".
- SOC, VisualDX, and NEJM Group Launch Webinar Series to Explore Issues in Skin Colorhttps://practicaldermatology.com/news/soc-visualdx-and-nejm-group-launch-webinar-series-to-explore-issues-in-skin-color/2460570/“The Impact of Skin Color and Ethnicity on Clinical Diagnosis and Research,” a new webinar series presented by the Skin of Color Society, NEJM Group, and VisualDx launches this month to call attention to health disparities and structural racism in medicine.
- Coverage Update: Cigna to Cover Excimer Laser Treatment for Vitiligohttps://practicaldermatology.com/news/coverage-update-cigna-to-cover-excimer-laser-treatment-for-vitiligo/2460566/Cigna, a global health services company offering health, pharmacy, dental and Medicare plans to both individuals and businesses covering over 20 million people in the United States, has issued a new medical coverage policy for excimer laser therapy vitiligo. STRATA Skin Sciences, maker of the XTR
- ADCS Acquires Montgomery Dermatology; Catawba Research Enters Partnershiphttps://practicaldermatology.com/news/adcs-acquires-montgomery-dermatology-catawba-research-enters-partnership/2460565/Advanced Dermatology and Cosmetic Surgery (ADCS), the largest dermatology practice in the US, has acquired Dermatology Associates of Montgomery, a leading dermatology practice based in the Southeast. Bundy Group served as exclusive financial advisor to Dr. Steve Maddox, owner of Dermatology
- Data Confirm Efficacy, Safety of Nutrafol for Menopausal Womenhttps://practicaldermatology.com/news/data-confirm-efficacy-safety-of-nutrafol-for-menopausal-women/2460563/Administration of Nutrafol’s Women’s Balance formulationis safe and effective in improving hair growth and quality in women going through menopausal transition, according to new data. Presented in a poster presentation at the Annual Meeting of the American Society for D
- It's a Deal: Allergan Buys Luminera Dermal-Filler Businesshttps://practicaldermatology.com/news/its-a-deal-allergan-buys-luminera-dermal-filler-business/2460556/Allergan Aesthetics, an AbbVie company, has acquired Luminera's full dermal filler portfolio and R&D pipeline. Luminera is a privately held aesthetics company based in Israel with a portfolio and pipeline of dermal filler products. "
- Cynosure Launches FlexSure in US and Canadahttps://practicaldermatology.com/news/cynosure-launches-flexsure-device/2460552/Cynosure is launching FlexSure, the latest addition to the TempSure platform, in the US and Canada. FlexSure is a wrappable radiofrequency (RF) applicator for hands-free treatment on all patients and all skin types. With peel-and-sti
- With Label Extension, Simponi Aria Approved for PsA in Kids as Young as Twohttps://practicaldermatology.com/news/with-label-extension-simponi-aria-approved-for-psa-in-kids-as-young-as-two/2460549/The FDA has approved Simponi Aria (golimumab) for the treatment of active pJIA for patients two years of age and older and has extended the PsA indication for this same patient population. In Phase 3 clinical trials with pediatric patients, pharmacokinetic (PK) exposure of
- Practical Dermatology® magazine, Modern Aesthetics® magazine Recognized For Excellence by Folio: Magazinehttps://practicaldermatology.com/news/practical-dermatology-magazine-modern-aesthetics-magazine-recognized-for-excellence-by-folio-magazine/2460546/Bryn Mawr Communications III, LLC is pleased to announce that Practical Dermatology® magazine and sister publication Modern Aesthetics® magazine took home two Honorable Mentions from Folio: Magazine’s 2020 Eddie & Ozzie Awards, including a nod for Editorial Tea
- Industry Responds to COVID-19: BTL Gives Backhttps://practicaldermatology.com/news/coping-with-covid-19-btl-gives-back/2460542/BTL is revamping several of their manufacturing facilities to provide face masks and ventilators to the medical community. As of September 2020, BTL's European manufacturing facilities have been producing ventilators and masks including 
- Forte Biosciences, Inc. Announces First Patient Dosed in Study of FB-401 for the Treatment of Children and Adults With ADhttps://practicaldermatology.com/news/forte-biosciences-inc-announces-first-patient-dosed-in-study-of-fb-401-for-the-treatment-of-children-and-adults-with-ad/2460541/The first patient has been dosed in Forte Biosciences, Inc.’s clinical trial of FB-401 for the treatment of atopic dermatitis (AD). The multi-center, placebo controlled clinical trial of FB-401 is expected to enroll approximately 124 pediatric, adolescent and adult subjects aged 2